IL6 and neoplasm: The results demonstrated that UCMSCs-Tandab (IL-6/CD20) targeting CD20-positive DLBCL cells, evidenced by bounding to CD20-positive SU-DHL-2/4 cells, inhibit the proliferation of tumor cells by downregulating IL-6-related signaling pathway.